The global veterinary reference laboratory market was valued at USD 5.4 billion in 2025 and is projected to reach USD 12.1 billion by 2033, growing at a CAGR of 10.9% between 2026 and 2033. Growth is being driven by rising demand for early disease detection in pets, zoonotic disease surveillance, and outsourced high-complexity testing. North America leads with a 42.5% revenue share, while Asia Pacific is the fastest-growing region. Companion animals, clinical chemistry, and clinical pathology are the largest segments by animal type, technology, and application, respectively.

What Is a Veterinary Reference Laboratory, and Why Does It Matter Now

A veterinary reference laboratory is a centralized diagnostic facility that performs specialized, high-complexity testing that in-clinic analyzers cannot handle — histopathology, next-generation sequencing, advanced immunoassays, and confirmatory infectious disease panels. Where a veterinary clinic's in-house machine can flag an abnormal blood value, it's the reference lab that tells a vet why it's abnormal.

That distinction is becoming commercially important. As pet ownership matures into long-term, insurance-backed healthcare relationships, and as livestock economies scale up disease surveillance, the diagnostic bottleneck has shifted from "can we test" to "can we test with enough depth, speed, and accuracy." Reference labs sit exactly at that bottleneck, which is why the sector is compounding faster than veterinary care spending as a whole.

Download a free sample report or claim your copy of this full market intelligence report

Market Drivers: Why Growth Is Accelerating Through 2033

Rising demand for early and preventive diagnosis in companion animals. Pet owners are increasingly treating aging pets and mild symptoms the way human patients treat annual checkups — as an opportunity to catch cancer, endocrine disorders, and organ dysfunction before they become emergencies. This behavioral shift is pushing more samples out of the clinic and into centralized labs equipped for oncology panels and specialist pathology review.

Zoonotic disease surveillance and food safety mandates. Avian influenza, mpox, and other emerging zoonotic threats have pushed public health bodies — including the WHO, WOAH, FAO, and the CDC's zoonotic disease programs — toward a "One Health" model that links animal and human disease monitoring. This directly increases the volume of standardized, accredited testing that only reference labs can deliver at scale.

Consolidation and network build-out through M&A. Large diagnostic groups are acquiring regional labs to expand geographic coverage and cut turnaround times, rather than building capacity organically. This is arguably the least-discussed driver in the market: growth isn't only coming from more testing, it's coming from labs getting structurally closer to the clinics that feed them samples, which raises referral volume independent of underlying disease incidence.

Rising complexity of the test menu itself. Real-time PCR, next-generation sequencing, digital pathology, and AI-assisted image analysis in cytology are expanding what counts as "routine" specialist testing. Every new assay a reference lab validates effectively creates a new revenue line that in-clinic testing cannot replicate, which is a structural tailwind distinct from volume growth.

Livestock intensification and export certification. In production animal markets, disease control programs and export-driven certification requirements (particularly in Brazil, China, and parts of the Middle East) are mandating confirmatory lab testing as a condition of trade, not just herd health.

Key Segments Shaping the Market

By animal type, companion animals accounted for roughly 64% of 2025 revenue, driven by chronic disease monitoring, oncology testing, and rising pet insurance penetration. Production animals, though smaller today, are forecast to grow fastest through 2033 as commercial livestock operations scale testing frequency to protect herd productivity and meet export standards.

By technology, clinical chemistry remains the largest category because it underpins routine metabolic and organ-function screening across nearly every case type. The faster-growing category, however, is immunodiagnostics — antigen/antibody assays used in infectious and immune-mediated disease testing — as surveillance programs expand test menus beyond routine chemistry.

By application, clinical pathology (hematology and cytology) dominates because it drives most day-to-day treatment decisions. Interestingly, pregnancy testing is the fastest-growing application, at a projected 11.2% CAGR, reflecting expanding breeding programs in both livestock and companion animals — a segment that gets far less analyst attention than oncology or infectious disease testing despite its strong unit economics.

By end use, veterinary hospitals and clinics are both the largest and fastest-growing customer base, since limited in-house testing capacity makes outsourcing structurally necessary rather than optional. Academic and research institutions form a smaller but fast-growing segment, anchored by long-term contracts tied to epidemiological research.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Key Regions and the Companies Leading Them

North America holds the largest share of the market (42.5% in 2025), led by the U.S., where dense clinic networks, strong pet insurance adoption, and mature referral pathways for oncology and endocrinology testing sustain high sample volumes.

Europe is defined less by volume growth and more by regulatory depth — standardized surveillance frameworks and accreditation requirements make reference labs structurally indispensable rather than a convenience.

Asia Pacific is the fastest-growing region, propelled by urbanization, rising companion animal ownership in China and India, and government-backed livestock disease monitoring. This is also the region where local infrastructure investment (new BSL-3 labs, national reference facilities) is most visible — a signal that capacity, not just demand, is catching up.

Latin America and the Middle East & Africa are smaller in absolute terms but are seeing outsized investment relative to market size, largely tied to export-oriented livestock economies (Brazil) and government-led biosecurity programs (Saudi Arabia, South Africa).

On the competitive side, the market is moderately to highly concentrated. IDEXX Laboratories, Zoetis, Mars (through Antech), and Vimian control a disproportionate share of testing volumes through broad test menus, integrated digital reporting, and entrenched clinic referral relationships. Recent moves — Vimian's acquisition of Italy's I-Vet and Zoetis's purchase of the Veterinary Pathology Group in the UK and Ireland — illustrate a clear pattern: incumbents are buying regional density rather than competing purely on price or turnaround time. For smaller, independent labs, this raises the practical bar for competing, since referral relationships and digital integration are becoming as important as diagnostic accuracy itself.

What This Means Going Forward

The veterinary reference laboratory market is no longer simply "growing with pet ownership." It is being reshaped by three converging forces: consumer healthcare expectations moving from reactive to preventive, public health systems treating animal surveillance as inseparable from human health policy, and a wave of consolidation that is turning diagnostic reach into a competitive moat. Stakeholders evaluating this space should watch immunodiagnostics and pregnancy testing as under-covered growth pockets, and Asia Pacific's infrastructure build-out as the region most likely to surprise on the upside through 2033.

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage. 

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.